NCT04782687
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma treatment 2 recruiting NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL No drug interventions treatment 1 recruiting NCT01239368
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma treatment 1 / 2 terminated NCT02057640
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma treatment 1 / 2 completed NCT04999085
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma No drug interventions supportive_care Not Available completed NCT05228470
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. treatment 1 / 2 active_not_recruiting NCT05745285
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care No drug interventions supportive_care Not Available not_yet_recruiting NCT05763563
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy No drug interventions supportive_care Not Available recruiting NCT06066359
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT06518551
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM treatment 1 / 2 not_yet_recruiting NCT03302403
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors treatment Not Available unknown_status NCT03836690
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation No drug interventions treatment 1 unknown_status NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation treatment 2 recruiting NCT04843579
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients treatment 2 terminated NCT03574454
Machine Learning in Myeloma Response No drug interventions diagnostic Not Available unknown_status NCT00473551
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies treatment 1 terminated NCT01237951
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma treatment 2 completed NCT01518153
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) treatment 2 terminated NCT04751877
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). treatment 3 active_not_recruiting NCT01985477
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 terminated NCT03500445
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma treatment 2 active_not_recruiting NCT01531998
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) treatment 1 / 2 completed NCT01885897
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT treatment 1 / 2 completed NCT01116128
Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients treatment 2 terminated NCT00943293
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies treatment 1 terminated NCT05625971
Non-invasive MRD Assessment in Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT01413178
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma treatment 3 completed NCT00005988
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy treatment 1 completed NCT05353907
Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma No drug interventions Not Available Not Available not_yet_recruiting NCT00469209
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients treatment 1 / 2 completed NCT03641456
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma treatment 2 recruiting NCT04703985
Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology No drug interventions Not Available Not Available completed NCT02188537
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma treatment 2 completed NCT00606437
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants No drug interventions treatment 1 completed NCT01904175
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant No drug interventions Not Available Not Available completed NCT00578942
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath treatment 2 completed NCT05393999
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations No drug interventions prevention 2 withdrawn NCT04268199
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment treatment 2 recruiting NCT02356549
African American Cancer Clinical Trial Decisions: Testing Tailored Messages No drug interventions other Not Available completed NCT04614636
FT538 in Subjects With Advanced Hematologic Malignancies treatment 1 terminated NCT03314636
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. treatment 2 active_not_recruiting NCT01927718
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) treatment Not Available terminated NCT00891618
Acupuncture for Chemo-Induced Peripheral Neuropathy No drug interventions treatment 2 completed NCT00990717
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies treatment 1 completed NCT00580034
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath treatment 2 completed NCT02579824
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma No drug interventions treatment 1 terminated NCT00070616
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support treatment 1 completed NCT01526096
Stem Cell Transplantation for Patients With Multiple Myeloma treatment 1 active_not_recruiting NCT04407858
Cardiovascular Complications of Carfilzomib No drug interventions Not Available Not Available unknown_status NCT01916135
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative No drug interventions diagnostic 1 completed NCT05055063
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma treatment 1 recruiting NCT01039025
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma treatment 2 completed NCT04685525
Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT No drug interventions supportive_care Not Available withdrawn NCT03135925
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation No drug interventions treatment Not Available completed NCT03244930
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation treatment 2 unknown_status NCT00660166
Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions No drug interventions treatment 1 completed NCT04952766
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults No drug interventions other 4 completed NCT05065866
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy treatment 1 active_not_recruiting NCT05154474
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy No drug interventions Not Available Not Available unknown_status NCT00466674
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning No drug interventions treatment 2 completed NCT03371420
PET Imaging of Subjects Using 124I-PU-AD No drug interventions diagnostic 0 terminated NCT04320420
Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²) No drug interventions supportive_care Not Available recruiting NCT03951220
The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss No drug interventions Not Available Not Available completed NCT03862131
PROactive Evaluation of Function to Avoid CardioToxicity No drug interventions supportive_care 2 terminated NCT03776331
Vascular Functions in Myeloma Patients During Anti-tumor Therapy No drug interventions Not Available Not Available unknown_status NCT01245673
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma treatment 2 completed NCT02907073
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter diagnostic 1 / 2 terminated NCT03832127
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients diagnostic 1 recruiting NCT00242827
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma treatment 2 terminated NCT01191060
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years treatment 3 completed NCT06007989
Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME) No drug interventions Not Available Not Available not_yet_recruiting NCT03695744
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma treatment 2 active_not_recruiting NCT04194840
Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT No drug interventions supportive_care Not Available recruiting NCT01042704
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma treatment 1 completed NCT04680468
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma treatment 2 recruiting NCT05622669
Understanding Patterns of Fatigue in Health and Disease No drug interventions Not Available Not Available active_not_recruiting NCT06250595
European Rare Blood Disorders Platform (ENROL) No drug interventions Not Available Not Available recruiting NCT01700608
Prospective Observational Study on Plerixafor After Chemotherapy Not Available Not Available completed NCT06450821
PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications No drug interventions supportive_care Not Available not_yet_recruiting NCT05889221
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma No drug interventions treatment Not Available active_not_recruiting NCT02114502
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma treatment 2 withdrawn NCT02403102
Imageguided Theranostics in Multiple Myeloma No drug interventions Not Available Not Available completed NCT05528887
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies treatment 1 recruiting NCT00195533
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Not Available Not Available completed NCT02066454
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs treatment 3 unknown_status NCT01793051
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma treatment 2 completed NCT06487247
HEME Home Transfusion Program No drug interventions supportive_care Not Available not_yet_recruiting NCT00428545
Bevacizumab and Bortezomib in Patients With Advanced Malignancy treatment 1 completed NCT03704597
Cryotherapy Against Oral Mucositis After High-dose Melphalan No drug interventions treatment Not Available unknown_status NCT01283997
Prevention of Treatment Induced Neuropathy in Multiple Myeloma treatment 2 completed NCT00794261
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma treatment 2 completed NCT01016028
Chemotherapy-Induced Peripheral Neuropathy Survey No drug interventions Not Available Not Available withdrawn NCT01521611
Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy No drug interventions treatment 1 / 2 completed NCT01269593
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study diagnostic 0 active_not_recruiting NCT03702088
Place of the Hevylite Test in the Evaluation of MRD in Myeloma No drug interventions Not Available Not Available unknown_status NCT05203809
Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies No drug interventions Not Available Not Available unknown_status NCT03702309
Liquid Biopsy Evaluation and Repository Development at Princess Margaret No drug interventions Not Available Not Available recruiting NCT03006315
Mobile Health Device Study for Myeloma Patients No drug interventions Not Available Not Available active_not_recruiting NCT01875237
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene treatment 1 / 2 terminated NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma treatment 1 recruiting NCT02598752
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation No drug interventions Not Available Not Available completed NCT01517152
Testing a Spanish Version of a Patient Toxicity Questionnaire No drug interventions Not Available Not Available completed NCT00907452
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone other Not Available completed NCT01432600
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide treatment 1 / 2 completed NCT01543100
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy No drug interventions basic_science Not Available completed NCT03398200
Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma No drug interventions treatment 2 completed NCT01396200
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine treatment 0 completed NCT01220375
PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma treatment 2 completed NCT02931942
Changing Over Time of Ascorbic Acid After Chemotherapy No drug interventions Not Available Not Available active_not_recruiting NCT03238599
Pedometer Activity Monitoring After ASCT No drug interventions other 2 completed NCT06430736
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) treatment 2 recruiting NCT01079936
Lenalidomide and High-Dose Melphalan treatment 1 / 2 completed NCT00871013
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy treatment 2 active_not_recruiting NCT00943319
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies treatment 1 / 2 completed NCT01332617
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma treatment 2 withdrawn NCT01350258
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps treatment 1 / 2 terminated NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives treatment 2 terminated NCT01807286
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis treatment 1 terminated NCT00164086
Atorvastatin in Myeloma treatment 1 unknown_status NCT00800839
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide treatment 2 completed NCT00344422
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma treatment 3 completed NCT01240525
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers No drug interventions treatment 2 unknown_status NCT03556748
WB-EMS and Nutrition in Patients With Hematological Malignancies No drug interventions supportive_care Not Available unknown_status NCT01095757
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection treatment 2 completed NCT02542657
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT03373526
Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation No drug interventions treatment Not Available unknown_status NCT01302366
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma No drug interventions treatment 2 terminated NCT00439465
Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma No drug interventions treatment 2 completed NCT00430365
Maintenance Therapy Using Lenalidomide in Myeloma treatment 3 completed NCT02027220
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma treatment 2 unknown_status NCT00881920
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL No drug interventions treatment 1 recruiting NCT00410982
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies treatment 1 completed NCT01174082
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant treatment 2 terminated NCT00001582
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer No drug interventions Not Available Not Available completed NCT01440582
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients treatment 1 completed NCT03131531
Bergamo Lymphoid Cancer Registry No drug interventions Not Available Not Available recruiting NCT05182073
FT576 in Subjects With Multiple Myeloma treatment 1 active_not_recruiting NCT04862676
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT No drug interventions treatment 0 recruiting NCT00698776
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma treatment 1 completed NCT06153576
The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures No drug interventions Not Available Not Available completed NCT01279694
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) treatment 1 / 2 completed NCT00476294
Long-Term Follow Up Study for AMD3100 Patients No drug interventions Not Available Not Available completed NCT03184194
Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide treatment 2 completed NCT05063591
Removing Transfusion Dependence as a Barrier to Hospice Enrollment No drug interventions supportive_care Not Available active_not_recruiting NCT00361140
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) treatment 4 completed NCT01861340
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma basic_science 0 completed NCT01624701
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells No drug interventions treatment 1 / 2 terminated NCT00983346
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients prevention 2 terminated NCT03618212
MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis? No drug interventions Not Available Not Available terminated NCT03591614
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma No drug interventions treatment 0 withdrawn NCT00597714
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant No drug interventions treatment 2 completed NCT03633955
Pilot Imaging Study of Leukemia No drug interventions diagnostic 1 recruiting NCT01248455
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma No drug interventions treatment 2 terminated NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed NCT02140736
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology No drug interventions Not Available Not Available completed NCT05011045
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies No drug interventions Not Available Not Available active_not_recruiting NCT04892264
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma treatment 1 / 2 completed NCT01718743
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma treatment 2 completed NCT03870451
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma No drug interventions device_feasibility Not Available terminated NCT03858205
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma No drug interventions treatment Not Available recruiting NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT03119883
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma No drug interventions basic_science Not Available completed NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT03311828
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma diagnostic 1 completed NCT05892393
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma No drug interventions diagnostic 1 recruiting NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study No drug interventions Not Available Not Available recruiting NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT03793907
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma No drug interventions supportive_care Not Available completed NCT05208307
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma treatment 2 recruiting NCT04270409
A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma treatment 3 active_not_recruiting NCT03958656
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma treatment 1 completed NCT05918185
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT03141437
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer No drug interventions health_services_research Not Available active_not_recruiting NCT00064337
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis treatment 2 completed NCT03078452
Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy No drug interventions diagnostic Not Available completed NCT01864018
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis treatment 1 / 2 active_not_recruiting NCT02389517
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant treatment 2 active_not_recruiting NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT03346135
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 active_not_recruiting NCT00900263
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma No drug interventions Not Available Not Available completed NCT05274763
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant No drug interventions supportive_care Not Available completed NCT02513186
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation treatment 1 completed NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT03477539
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma treatment 2 active_not_recruiting NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT04876248
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant treatment 2 recruiting NCT00525057
Dalteparin in Preventing DVT in Participants With Cancer prevention Not Available completed NCT02944565
Daratumumab in Treating Patients With Multiple Myeloma treatment 2 completed NCT04000282
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 completed NCT02619682
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 active_not_recruiting NCT04458831
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) Not Available Not Available recruiting NCT04465760
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy No drug interventions supportive_care 2 terminated NCT02547662
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia treatment 2 completed NCT04100044
Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma No drug interventions health_services_research Not Available completed NCT02215967
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma treatment 1 completed NCT01055301
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma treatment 2 withdrawn NCT04530812
Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma No drug interventions supportive_care Not Available completed NCT00146055
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT03303950
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis treatment 2 terminated NCT01863550
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma treatment 3 active_not_recruiting NCT02492750
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma treatment 1 completed NCT04579523
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma treatment 1 not_yet_recruiting NCT02990338
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients treatment 3 completed NCT04282343
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer No drug interventions health_services_research Not Available completed NCT03417284
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation treatment 1 / 2 completed NCT05561387
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment treatment 3 recruiting NCT03272633
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies No drug interventions treatment 0 terminated NCT03870633
Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma No drug interventions Not Available Not Available completed NCT00600353
Multi-day Doses in Prevention of Nausea and Emesis supportive_care 2 completed NCT03100877
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma treatment 1 / 2 withdrawn NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT02538198
Lenalidomide Maintenance in Plasma Cell Myeloma treatment 2 active_not_recruiting NCT04352205
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure treatment 2 terminated NCT03192397
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT05511428
Home Based Daratumumab Administration for Patients With Multiple Myeloma treatment 0 active_not_recruiting NCT04566328
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial treatment 3 recruiting NCT02880228
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant treatment 2 completed NCT05142371
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors No drug interventions supportive_care Not Available active_not_recruiting NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 3 completed NCT04221178
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission No drug interventions Not Available Not Available recruiting NCT03275285
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients treatment 3 active_not_recruiting NCT05053100
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study No drug interventions Not Available Not Available recruiting NCT04211259
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization treatment 0 recruiting NCT02283775
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients treatment 1 completed NCT01251575
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant treatment 2 completed NCT04466475
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma treatment 1 withdrawn NCT01503242
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 completed NCT05005299
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation treatment 1 recruiting NCT03317899
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma treatment 2 completed NCT01547806
Collection of Transplant Stem Cells for Plasma Cell Myeloma treatment 2 completed NCT01919619
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies treatment 1 completed NCT02700841
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation treatment 2 terminated NCT04977024
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer treatment 2 recruiting NCT03942224
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma treatment 2 active_not_recruiting NCT03756896
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma treatment 2 active_not_recruiting NCT00421525
Phase I/II Study of hLL1 in Multiple Myeloma treatment 1 / 2 completed NCT02334865
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy treatment 1 active_not_recruiting NCT05204160
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy treatment 2 withdrawn NCT02420860
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma treatment 2 active_not_recruiting NCT01729091
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 completed NCT05288062
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma treatment 2 active_not_recruiting NCT03012880
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma treatment 2 completed NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab treatment 2 recruiting NCT04065789
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients treatment 2 completed NCT03194867
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients treatment 1 / 2 completed NCT03319667
Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant treatment 3 active_not_recruiting NCT02566304
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT02353572
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 / 2 terminated NCT02514668
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma treatment 1 completed NCT01749969
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients treatment 1 completed NCT05392946
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study treatment 1 / 2 recruiting NCT02960646
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT03602612
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma treatment 1 active_not_recruiting NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 completed NCT05312255
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma treatment Not Available recruiting NCT02955043
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery No drug interventions supportive_care Not Available completed NCT06592222
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies Not Available Not Available active_not_recruiting NCT06610045
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study No drug interventions Not Available Not Available enrolling_by_invitation NCT00352924
Agriculture Health Study No drug interventions Not Available Not Available active_not_recruiting NCT00747123
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma treatment 2 completed NCT01676805
Tissue Collection for Studies of Lymph Cancer No drug interventions Not Available Not Available recruiting NCT02253316
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma treatment 2 active_not_recruiting NCT02294487
Study of the Immune Response After Vaccination in Multiple Myeloma Patients No drug interventions Not Available Not Available completed NCT02298816
B-Cell Hematologic Malignancy Vaccination Registry No drug interventions Not Available Not Available withdrawn NCT02356159
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation treatment 1 / 2 active_not_recruiting NCT02375555
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM treatment 2 completed NCT02441686
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma treatment 2 active_not_recruiting NCT02473757
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies No drug interventions Not Available Not Available enrolling_by_invitation NCT02682667
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols No drug interventions Not Available Not Available recruiting NCT02909036
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. treatment 1 active_not_recruiting NCT03412877
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer treatment 2 recruiting NCT03595800
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen No drug interventions treatment 3 completed NCT03761108
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT03896737
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara treatment 2 active_not_recruiting NCT03994705
Descartes-11 in Multiple Myeloma treatment 1 terminated NCT04314401
National Cancer Institute "Cancer Moonshot Biobank" No drug interventions Not Available Not Available recruiting NCT04497961
A Study of Health-Related Quality of Life in People with Multiple Myeloma Receiving Daratumumab or Lenalidomide treatment 2 recruiting NCT06623630
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function treatment 1 not_yet_recruiting NCT04933539
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma treatment 2 active_not_recruiting NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers treatment 1 active_not_recruiting NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments treatment 1 recruiting NCT05284591
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) Not Available Not Available completed NCT05646836
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma treatment 1 recruiting NCT05650632
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT05775094
A Study of Romosozumab in Women with Multiple Myeloma and Osteoporosis treatment 1 active_not_recruiting NCT05887167
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects with Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 recruiting NCT05954780
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma Not Available Not Available recruiting NCT05971056
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma No drug interventions health_services_research Not Available terminated NCT06066346
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy treatment 2 recruiting NCT06103838
18F-Fluciclovine PET/CT in Multiple Myeloma treatment 2 recruiting NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers treatment 1 / 2 recruiting NCT06158841
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma treatment 3 recruiting NCT06223516
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT04555551
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma No drug interventions treatment 1 active_not_recruiting NCT04586426
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT04649359
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb treatment 2 active_not_recruiting NCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma treatment 1 active_not_recruiting NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies treatment 1 active_not_recruiting NCT04773522
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT04892446
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma treatment 2 completed NCT04923893
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy treatment 3 active_not_recruiting NCT04975997
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) treatment 3 recruiting NCT05013190
A Study of NINLARO® in Chinese Adults With Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT05020236
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma treatment 3 active_not_recruiting NCT05027594
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma treatment 1 terminated NCT05050097
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma treatment 1 active_not_recruiting NCT05083169
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma treatment 3 active_not_recruiting NCT05123001
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events No drug interventions supportive_care Not Available recruiting NCT05123131
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma treatment 2 recruiting NCT05177536
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma treatment 2 withdrawn NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel other 4 recruiting NCT05289492
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT05317416
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant treatment 3 recruiting NCT05354557
Study of Iberdomide in People with Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) treatment 2 recruiting NCT05438043
A Study of Daratumumab treatment 3 recruiting NCT05444348
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT) No drug interventions supportive_care Not Available recruiting NCT05535244
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma treatment 3 recruiting NCT05565638
PROFAST Intervention in Precursor Multiple Myeloma No drug interventions prevention Not Available recruiting NCT05583617
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma treatment 1 / 2 recruiting NCT05590377
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant treatment 3 recruiting NCT05640843
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) No drug interventions prevention Not Available recruiting NCT05642884
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation No drug interventions prevention Not Available recruiting NCT05673083
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT05776979
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients treatment 2 recruiting NCT05823571
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients treatment 1 recruiting NCT05827016
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma treatment 3 recruiting NCT05846880
VitD3 Supplementation in Patients with Multiple Myeloma treatment 0 not_yet_recruiting NCT05976555
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma No drug interventions treatment 1 not_yet_recruiting NCT06042725
Venetoclax in Combination with Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma treatment 1 recruiting NCT06045806
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation treatment 3 active_not_recruiting NCT06052826
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study No drug interventions supportive_care 2 recruiting NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma treatment 1 recruiting NCT06126341
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders No drug interventions Not Available Not Available recruiting NCT06142396
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients with Renal Failure treatment 0 not_yet_recruiting NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) treatment 3 recruiting NCT06169215
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma treatment 2 recruiting NCT06179888
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma treatment 2 recruiting NCT06207799
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma treatment 2 recruiting NCT06270888
Hypofractionation (Radiation) Trial for Multiple Myeloma No drug interventions treatment 1 recruiting NCT06280924
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma No drug interventions supportive_care Not Available recruiting NCT06297226
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 2 recruiting NCT06348147
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation treatment 2 not_yet_recruiting NCT06376526
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma treatment 2 recruiting NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 recruiting NCT06413498
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants with Relapsed/ Refractory Multiple Myeloma treatment 3 recruiting NCT06461988
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma treatment 2 not_yet_recruiting NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma treatment 1 not_yet_recruiting NCT06477783
Study on the Clinical Efficacy of Teclistamab Not Available Not Available not_yet_recruiting NCT06523621
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel treatment 2 not_yet_recruiting NCT06539832
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients No drug interventions Not Available Not Available recruiting NCT06547112
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization treatment 1 not_yet_recruiting NCT06550895
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma treatment 2 recruiting NCT06559709
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant No drug interventions supportive_care Not Available recruiting NCT06561854
Study Comparing Therapy for Advanced Relapsed/refractory Multiple Myeloma with and Without Dexamethasone treatment 3 not_yet_recruiting NCT06577025
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma treatment 2 recruiting NCT06581640
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma No drug interventions treatment 2 recruiting NCT06588413
Olanzapine 2.5 Vs 5 Mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan prevention 3 not_yet_recruiting NCT06594211
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma treatment Not Available not_yet_recruiting NCT06616389
Study of ODX (OsteoDex) in Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT02389543
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients treatment 1 / 2 withdrawn NCT00561743
A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients treatment 2 completed NCT02275403
Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma No drug interventions treatment 2 completed NCT03977103
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT No drug interventions treatment 2 unknown_status NCT04805203
Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma No drug interventions diagnostic Not Available terminated NCT00720603
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. Not Available Not Available no_longer_available NCT01269203
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients treatment 2 withdrawn NCT02272803
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan treatment 2 completed NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies treatment 1 completed NCT01643603
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies treatment 1 terminated NCT05789303
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma treatment 2 recruiting NCT00352703
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation prevention 4 completed NCT00229203
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma treatment 2 completed NCT01296503
Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma treatment 3 completed NCT01105403
Exploratory Study on POL6326 in Stem Cell Mobilization No drug interventions treatment 2 completed NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT00701103
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) treatment 1 completed NCT02206503
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) treatment 2 completed NCT05203003
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment. No drug interventions Not Available Not Available recruiting NCT06063603
Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study No drug interventions supportive_care Not Available completed NCT05858203
Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment No drug interventions Not Available Not Available recruiting NCT01050790
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma treatment Not Available completed NCT01179490
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma treatment 2 terminated NCT00473590
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) treatment 2 completed NCT00333190
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation No drug interventions prevention Not Available completed NCT05932290
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma Not Available Not Available completed NCT04260490
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study. No drug interventions Not Available Not Available unknown_status NCT00038090
Thalidomide-Dexamethasone for Multiple Myeloma treatment 2 / 3 completed NCT02405364
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction treatment 2 unknown_status NCT03782064
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma treatment 2 terminated NCT00048464
T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant No drug interventions treatment 1 / 2 unknown_status NCT01204164
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies treatment 1 completed NCT00300664
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Not Available 2 / 3 completed NCT03652064
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy treatment 3 active_not_recruiting NCT00083564
Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma No drug interventions treatment 3 terminated NCT05236621
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma treatment 3 unknown_status NCT00368121
EMMA-1 (Erbitux for Multiple Myeloma) treatment 2 terminated NCT00062621
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure No drug interventions treatment 1 completed NCT00925821
Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma No drug interventions treatment 2 completed NCT03931421
B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma No drug interventions treatment 2 unknown_status NCT05911321
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM treatment 2 recruiting NCT03757221
Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma treatment 2 recruiting NCT04242121
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood No drug interventions Not Available Not Available terminated NCT00128921
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma prevention 2 terminated NCT00970021
Agaricus Blazei Murill in Patients With Multiple Myeloma No drug interventions treatment 2 completed NCT00872521
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma treatment 2 completed NCT00412321
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease treatment 1 completed NCT05545202
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation No drug interventions treatment 4 not_yet_recruiting NCT02728102
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) treatment 2 completed NCT02921802
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules No drug interventions Not Available Not Available completed NCT02884102
MMRF Molecular Profiling Protocol No drug interventions Not Available Not Available active_not_recruiting NCT06366802
Cohort Construction and Prognostic Model Construction for Multiple Myeloma No drug interventions Not Available Not Available active_not_recruiting NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) treatment 4 recruiting NCT01030302
A Retreatment Study With Bortezomib for Multiple Myeloma Not Available Not Available completed NCT05573802
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma treatment 1 / 2 recruiting NCT00639002
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma treatment 2 completed NCT02248402
Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 unknown_status NCT00083902
Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy treatment 2 completed NCT02078102
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma treatment 2 completed NCT03159702
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation treatment 2 recruiting NCT06409702
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Not Available Not Available not_yet_recruiting NCT05521802
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT06061302
Multiple Myeloma Yoga Pilot Study No drug interventions supportive_care Not Available suspended NCT06082284
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method. No drug interventions Not Available Not Available recruiting NCT01134484
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) treatment 3 unknown_status NCT01402284
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients treatment 2 completed NCT03915184
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) treatment 1 / 2 active_not_recruiting NCT05577884
Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT04024384
Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial treatment 2 withdrawn NCT00263484
Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma treatment 2 completed NCT00891384
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma treatment 3 completed NCT03785184
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy treatment 2 withdrawn NCT05690984
Elimination of Minimal Residual Disease After Transplant treatment 2 recruiting NCT04309084
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma treatment 1 active_not_recruiting NCT00255684
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer treatment Not Available terminated NCT04760184
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden No drug interventions Not Available Not Available completed NCT02178579
Prospective Observation of Cardiac Safety With Proteasome Inhibition No drug interventions Not Available Not Available completed NCT00124579
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT02095379
Oligosecretary Myeloma: Prevalence and Its Clinical Significance No drug interventions Not Available Not Available completed NCT01063179
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients treatment 3 completed NCT02916979
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG treatment 1 completed NCT02195479
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma treatment 3 active_not_recruiting NCT02612779
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. treatment 2 completed NCT01018979
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients No drug interventions treatment 2 completed NCT03543579
Cardiovascular Complications of Carfilzomib Treatment No drug interventions Not Available Not Available unknown_status NCT01171443
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy No drug interventions Not Available Not Available unknown_status NCT03607643
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies treatment 1 / 2 unknown_status NCT03966443
Fluciclovine PET/CT in Multiple Myeloma Patients No drug interventions Not Available Not Available recruiting NCT01067287
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation treatment 2 active_not_recruiting NCT01908387
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms treatment 1 terminated NCT01311687
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study treatment 3 completed NCT00415987
Hematopoietic Stem Cell Transplantation in Myeloma No drug interventions treatment 2 / 3 unknown_status NCT05001087
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) No drug interventions Not Available Not Available recruiting NCT02761187
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants No drug interventions Not Available Not Available completed NCT00135187
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma treatment Not Available completed NCT02861287
Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma No drug interventions Not Available Not Available completed NCT05636787
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients treatment 2 recruiting NCT05831787
COVID19 OutcomeS in Myeloma and the Impact of VaCcines No drug interventions Not Available Not Available active_not_recruiting NCT01190787
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone treatment 2 completed NCT02184533
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer treatment 1 completed NCT00833833
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma treatment 1 / 2 completed NCT02376933
Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer No drug interventions treatment Not Available terminated NCT03582033
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma treatment 1 terminated NCT05212233
Financial Difficulty in Patients With Blood Cancer No drug interventions Not Available Not Available recruiting NCT05844033
Biomarker for Infection Risk in CLL and MM No drug interventions Not Available Not Available recruiting NCT01521533
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma No drug interventions treatment 2 completed NCT00153933
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT04545333
The clonoSEQ® Watch Registry No drug interventions Not Available Not Available terminated NCT06109233
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment No drug interventions Not Available Not Available recruiting NCT01182233
Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation No drug interventions treatment 1 terminated NCT00038233
Thalidomide for Multiple Myeloma treatment 3 completed NCT02800954
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma No drug interventions diagnostic Not Available completed NCT01029054
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma health_services_research 1 / 2 completed NCT06105554
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT05372354
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT02559154
Modified Bortezomib-based Combination Therapy for Multiple Myeloma treatment 4 unknown_status NCT00896454
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium treatment 2 completed NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy Not Available Not Available recruiting NCT00065351
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma treatment 2 completed NCT04361851
Study of Dara-Pembro for Multiple Myeloma Patients treatment 2 withdrawn NCT00205751
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy treatment 2 / 3 completed NCT02160951
Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies treatment 1 completed NCT05561751
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant treatment 2 recruiting NCT03657251
MMRF CureCloud Research Initiative No drug interventions Not Available Not Available terminated NCT06185751
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma No drug interventions treatment 1 recruiting NCT03679351
"FU-IFM2009" Database Post IFM/DFCI 2009 Study No drug interventions Not Available Not Available unknown_status NCT01495351
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma treatment 1 completed NCT03767751
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 unknown_status NCT03068351
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma treatment 1 completed NCT02424851
Optimising Renal Outcome in Myeloma Renal Failure treatment 2 completed NCT00216151
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma prevention 2 terminated NCT01753453
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells treatment 2 completed NCT02204553
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma Not Available Not Available no_longer_available NCT00222053
IFM 99-02 Thalidomide in Myeloma treatment 3 completed NCT05190653
Early Integration of Palliative and Supportive Care in Cellular Therapy No drug interventions supportive_care Not Available recruiting NCT00089453
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant treatment 1 completed NCT06087653
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) treatment 1 / 2 recruiting NCT03748953
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) treatment 3 completed NCT02682953
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers treatment 2 withdrawn NCT00531453
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma treatment 2 completed NCT00706953
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib treatment 2 withdrawn NCT00657553
Preemptive Strike With Bortezomib in Multiple Myeloma Patients treatment 3 terminated NCT01432353
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 completed NCT06484777
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma No drug interventions treatment 1 recruiting NCT00083577
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma treatment 2 completed NCT03683277
IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic treatment 2 terminated NCT04853277
Patient Reported Outcomes and Patient Education in Cellular Therapy Patients No drug interventions prevention Not Available completed NCT01286077
Velcade Consolidation Bone Study treatment 2 completed NCT05381077
Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner No drug interventions diagnostic Not Available unknown_status NCT02576977
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) treatment 3 terminated NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT00773747
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) treatment 3 completed NCT06323447
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia No drug interventions Not Available Not Available not_yet_recruiting NCT05338047
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant prevention 2 completed NCT06407947
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma No drug interventions treatment 0 recruiting NCT02467647
The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy treatment 1 unknown_status NCT05065047
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma treatment 1 recruiting NCT05686447
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis No drug interventions Not Available Not Available recruiting NCT00790647
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis treatment 2 completed NCT00099047
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma prevention 2 completed NCT06566547
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 2 recruiting NCT04246047
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma treatment 3 active_not_recruiting NCT00702247
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) No drug interventions treatment 2 unknown_status NCT00165347
Protein Tyrosine Kinases (PTK) in Multiple Myeloma treatment 2 completed NCT01324947
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma treatment 3 completed NCT01536145
CP-751,871 Treatment For Patients With Multiple Myeloma treatment 1 completed NCT04398745
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function treatment 1 recruiting NCT03848845
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) treatment 1 / 2 completed NCT00461045
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma treatment 2 completed NCT02112045
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation treatment 2 terminated NCT03669445
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma treatment 2 recruiting NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT06203145
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM treatment Not Available recruiting NCT06314698
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease supportive_care 3 not_yet_recruiting NCT06041698
Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma No drug interventions health_services_research Not Available recruiting NCT04268498
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma treatment 2 recruiting NCT00777998
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma No drug interventions treatment 2 completed NCT05161598
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) Not Available Not Available no_longer_available NCT05556798
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment treatment 1 recruiting NCT04659798
A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice No drug interventions Not Available Not Available completed NCT02002598
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma treatment 1 / 2 completed NCT06163898
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT05050305
Marizomib Central Nervous System (CNS) treatment 2 withdrawn NCT05722405
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma treatment 4 recruiting NCT00656305
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain No drug interventions treatment Not Available completed NCT00323505
A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma No drug interventions Not Available 2 completed NCT04543305
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT00622505
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants prevention 4 completed NCT04730505
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM No drug interventions supportive_care 1 terminated NCT05163405
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma. Not Available Not Available completed NCT04760405
The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma No drug interventions supportive_care Not Available completed NCT01562405
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT02556905
A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea Not Available Not Available completed NCT00911105
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone No drug interventions Not Available Not Available completed NCT04453397
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma Not Available Not Available no_longer_available NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation treatment 3 recruiting NCT05594797
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM No drug interventions treatment 2 recruiting NCT00216697
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy treatment 2 completed NCT01454297
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile No drug interventions Not Available Not Available completed NCT01313897
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma prevention 2 completed NCT01239797
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma treatment 3 completed NCT01177397
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma treatment 1 / 2 completed NCT04124497
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients treatment 2 active_not_recruiting NCT03795597
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) treatment 1 / 2 unknown_status NCT02335983
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma treatment 1 completed NCT03570983
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion treatment 2 recruiting NCT02697383
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study treatment 1 completed NCT05712083
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma No drug interventions treatment 2 recruiting NCT00424983
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year treatment 1 completed NCT02030483
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma treatment 1 terminated NCT01583283
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma treatment 1 completed NCT04258683
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE treatment 2 withdrawn NCT03530683
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma treatment 1 terminated NCT00396383
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation treatment 2 terminated NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match treatment 2 terminated NCT02109861
Microdose Study of Melphalan, Bortezomib and Dexamethasone basic_science 0 unknown_status NCT00965861
SCRI Tissue Testing Registry No drug interventions Not Available Not Available terminated NCT04094961
Ixazomib + Pomalidomide + Dexamethasone In MM treatment 1 / 2 recruiting NCT02237261
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma treatment 2 completed NCT04223661
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy treatment 2 withdrawn NCT00116961
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma treatment 2 completed NCT00434161
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma supportive_care 3 completed NCT00131261
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma treatment 2 completed NCT02627261
Multiple Myeloma Minimal Residual Disease No drug interventions Not Available Not Available completed NCT00482261
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression treatment 2 unknown_status NCT02921828
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg No drug interventions Not Available Not Available completed NCT03475628
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma treatment 2 unknown_status NCT05556928
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry No drug interventions Not Available Not Available recruiting NCT03344328
Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. Not Available Not Available completed NCT06286228
Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease No drug interventions Not Available Not Available not_yet_recruiting NCT00551928
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients treatment 3 completed NCT03651128
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) treatment 3 active_not_recruiting NCT01868828
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma No drug interventions treatment 4 unknown_status NCT00242528
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. treatment 4 withdrawn NCT03106428
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 completed NCT04280328
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT02412228
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma treatment 2 unknown_status NCT01734928
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma treatment 3 completed NCT02348528
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year treatment 2 completed NCT02756728
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma treatment 1 / 2 terminated NCT01081028
Connect® MM- The Multiple Myeloma Disease Registry No drug interventions Not Available Not Available recruiting NCT00675428
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 terminated NCT01005628
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Not Available Not Available completed NCT02033928
Comprehensive Frailty Assessment No drug interventions Not Available Not Available completed NCT03430011
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma treatment 1 / 2 completed NCT06132711
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT04918511
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma No drug interventions treatment 1 withdrawn NCT00579111
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) treatment 1 / 2 terminated NCT04496011
Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation No drug interventions treatment Not Available unknown_status NCT05238311
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Not Available Not Available temporarily_not_available NCT02891811
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy treatment 2 completed NCT00003511
Antineoplaston Therapy in Treating Patients With Multiple Myeloma treatment 2 terminated NCT00401011
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients treatment 1 / 2 completed NCT00293111
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) treatment 2 terminated NCT00602511
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma treatment 3 completed NCT03089411
Collection of Additional Data Followed the Study IFM 2013-04 No drug interventions Not Available Not Available unknown_status NCT00211211
FREE Study - Fracture Reduction Evaluation No drug interventions other 4 completed NCT02007811
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination No drug interventions treatment 1 / 2 unknown_status NCT03440411
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment treatment 3 terminated NCT02976493
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma No drug interventions Not Available Not Available completed NCT03439293
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) treatment 2 completed NCT05478993
Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement treatment 2 recruiting NCT05147493
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment treatment 2 not_yet_recruiting NCT00602693
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer treatment 1 completed NCT05469893
Immuno-PRISM (PRecision Intervention Smoldering Myeloma) treatment 2 recruiting NCT01742793
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) treatment 1 terminated NCT05378971
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma treatment Not Available recruiting NCT01580371
Safety and Pharmacokinetic Profile of CKD-581 No drug interventions treatment 1 completed NCT04836871
Double Filtration Plasmapheresis Combined With Chemotherapy No drug interventions treatment 1 recruiting NCT01711671
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT02164071
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies No drug interventions Not Available Not Available completed NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product No drug interventions Not Available Not Available terminated NCT02023671
IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSE No drug interventions Not Available Not Available unknown_status NCT02937571
High Dose Carfilzomib for Newly Diagnosed Myeloma treatment 1 / 2 active_not_recruiting NCT02497378
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT02412878
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma treatment 3 completed NCT05016778
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma treatment 0 active_not_recruiting NCT02477878
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant treatment 1 active_not_recruiting NCT00464178
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma treatment 2 terminated NCT04771078
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release Not Available Not Available available NCT03525678
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody treatment 2 active_not_recruiting NCT03448978
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma treatment 1 terminated NCT05541978
Thrombosis in Patients With Multiple Myeloma in an University Medical Center No drug interventions Not Available Not Available completed NCT04008888
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients treatment Not Available unknown_status NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery No drug interventions Not Available Not Available completed NCT00657488
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma treatment 2 / 3 completed NCT00743288
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma treatment 1 / 2 completed NCT00722488
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma treatment 1 completed NCT01572688
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma treatment Not Available unknown_status NCT01453088
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older treatment 2 terminated NCT03548207
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT03975907
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) No drug interventions treatment 1 / 2 active_not_recruiting NCT04584307
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant treatment 2 withdrawn NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT00689507
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib treatment 1 completed NCT03773107
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma treatment 1 / 2 completed NCT06503107
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM No drug interventions treatment 1 / 2 recruiting NCT05053607
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab No drug interventions other Not Available recruiting NCT05840107
Study of FasT CAR-T GC012F Injection NDMM Patients No drug interventions treatment 0 recruiting NCT01160107
Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients treatment 2 completed NCT02270307
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis prevention 2 / 3 unknown_status NCT01270009
Role of BCL-B in Multiple Myeloma No drug interventions Not Available Not Available completed NCT04243109
Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib treatment 2 terminated NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans No drug interventions Not Available Not Available not_yet_recruiting NCT04111809
Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care No drug interventions Not Available Not Available recruiting NCT06359509
Study of SYS6020 in BCMA-positive Multiple Myeloma No drug interventions treatment 0 not_yet_recruiting NCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders treatment 2 completed NCT05346809
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma treatment 2 recruiting NCT00109109
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) treatment 1 terminated NCT01947309
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) Not Available Not Available terminated NCT03316209
Identification of Occupational Exposures in Acute Hematologic Malignancy No drug interventions Not Available Not Available completed NCT02666209
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma Not Available Not Available no_longer_available NCT02407509
Phase I Trial of VS-6766 Alone and in Combination With Everolimus treatment 1 recruiting NCT05114109
Isatuximab in Type I Cryoglobulinemia treatment 2 unknown_status NCT02851056
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) treatment 0 completed NCT04244656
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT02605356
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma treatment 1 / 2 withdrawn NCT00400556
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells treatment 1 completed NCT04802356
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients treatment 2 recruiting NCT02056756
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma treatment 1 / 2 completed NCT03481556
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM treatment 1 / 2 terminated NCT00698685
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation treatment 2 terminated NCT00720785
Natural Killer Cells and Bortezomib to Treat Cancer treatment 1 completed NCT05347485
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma treatment 2 completed NCT03143985
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma treatment 1 completed NCT02646085
Multiparametric Imaging in Multiple Myeloma diagnostic 1 completed NCT03374085
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) treatment 1 / 2 active_not_recruiting NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia treatment 1 completed NCT03779815
Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography diagnostic Not Available completed NCT05429515
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury No drug interventions treatment 4 not_yet_recruiting NCT00083915
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation treatment 3 completed NCT02117115
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation screening 0 completed NCT01450215
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma treatment 2 completed NCT01857115
Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) treatment 1 / 2 active_not_recruiting NCT02145715
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma treatment 1 / 2 unknown_status NCT02477215
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT01382615
Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research No drug interventions Not Available Not Available terminated NCT03710915
A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma No drug interventions treatment 1 terminated NCT05131815
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors No drug interventions supportive_care Not Available active_not_recruiting NCT00096837
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT04822337
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT00040937
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 completed NCT02852837
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy treatment 1 completed NCT04808037
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT05822037
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia No drug interventions treatment Not Available recruiting NCT06126237
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 not_yet_recruiting NCT05833737
Corneal Findings in Patients Treated With Belantamab Mafodotin Not Available Not Available not_yet_recruiting NCT00311337
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) treatment 2 unknown_status NCT03493737
Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma No drug interventions Not Available Not Available completed NCT01790737
First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02 treatment 2 completed NCT06062537
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients No drug interventions Not Available Not Available recruiting NCT04941937
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM treatment 2 recruiting NCT03068637
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma No drug interventions supportive_care Not Available completed NCT04702932
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies No drug interventions Not Available Not Available not_yet_recruiting NCT02906332
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) treatment 2 terminated NCT05737732
The Ambient Light Multiple Myeloma Study No drug interventions treatment Not Available recruiting NCT01315132
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies No drug interventions treatment 2 completed NCT01541332
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma treatment 1 / 2 unknown_status NCT04143932
Multiple Myeloma Turkish Prospective Patient Registry No drug interventions Not Available Not Available recruiting NCT05804032
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma treatment 3 recruiting NCT00908232
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD treatment 2 completed NCT01270932
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients treatment 2 completed NCT03421132
Multiple Myeloma Molecular Monitoring Study No drug interventions Not Available Not Available active_not_recruiting NCT02899052
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) treatment 2 active_not_recruiting NCT01554852
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients treatment 3 unknown_status NCT03746652
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma treatment 2 unknown_status NCT03357952
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma treatment 2 / 3 completed NCT01251952
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation treatment 1 terminated NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT02519452
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT06095752
Multiple Myeloma Prognostic Indices No drug interventions Not Available Not Available recruiting NCT03000452
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) treatment 2 completed NCT06385652
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma diagnostic 0 recruiting NCT01892852
Acupuncture for Chemotherapy-induced Peripheral Neuropathy No drug interventions treatment Not Available unknown_status NCT01818752
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma treatment 3 completed NCT01337752
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency treatment 2 completed NCT04186052
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma No drug interventions treatment 0 unknown_status NCT00872352
Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients No drug interventions diagnostic 3 unknown_status NCT05493800
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT No drug interventions prevention 2 active_not_recruiting NCT05536700
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma No drug interventions Not Available Not Available unknown_status NCT04039100
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease No drug interventions supportive_care Not Available completed NCT02902900
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice No drug interventions Not Available Not Available completed NCT01410500
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease Not Available Not Available approved_for_marketing NCT06483100
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry treatment 2 not_yet_recruiting NCT00564200
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning treatment 2 completed NCT00162500
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies No drug interventions treatment 2 withdrawn NCT00689000
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) treatment 1 / 2 completed NCT04126200
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) treatment 1 / 2 recruiting NCT00135200
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma treatment 2 active_not_recruiting NCT00872300
PHA-739358 for the Treatment of Multiple Myeloma No drug interventions supportive_care 2 terminated NCT03634800
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) treatment 2 terminated NCT03168100
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma treatment 2 withdrawn NCT00555100
Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma treatment 1 completed NCT01365559
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments treatment 1 / 2 completed NCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction treatment 2 not_yet_recruiting NCT04887259
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML treatment 1 / 2 active_not_recruiting NCT00911859
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients treatment 2 completed NCT02077959
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 terminated NCT00972959
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy treatment 2 completed NCT00995059
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 / 2 withdrawn NCT01141959
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients No drug interventions Not Available Not Available completed NCT00301275
Assessing Free Immunoglobulin Light Chains in Patients With Myeloma No drug interventions Not Available Not Available completed NCT04877275
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM treatment 2 recruiting NCT00532675
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. treatment 1 completed NCT00536575
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients treatment 1 / 2 completed NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT02112175
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM treatment 3 completed NCT05308875
Efficacy and Safety Evaluation of PD1-BCMA-CART No drug interventions treatment Not Available not_yet_recruiting NCT05581875
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory treatment 1 / 2 not_yet_recruiting NCT00558675
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy No drug interventions treatment 1 / 2 completed NCT01752075
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan Not Available Not Available completed NCT01720875
Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) treatment 2 completed NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT03145870
Prevalence of Asymptomatic Thrombosis in Multiple Myeloma No drug interventions other Not Available withdrawn NCT00781170
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma No drug interventions treatment 2 completed NCT01463670
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance treatment 2 completed NCT00998270
Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma No drug interventions treatment 2 / 3 unknown_status NCT03763370
Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Not Available Not Available available NCT03992170
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive treatment 2 unknown_status NCT01592370
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma treatment 1 / 2 completed NCT02919670
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma No drug interventions treatment Not Available completed NCT05964270
Telemonitoring Among Patients With Multiple Myeloma No drug interventions other Not Available recruiting NCT02874742
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma treatment 2 completed NCT03436342
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma No drug interventions diagnostic 0 unknown_status NCT05243342
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT03549442
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma No drug interventions basic_science 1 active_not_recruiting NCT00322842
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients treatment 2 completed NCT01001442
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT06015542
Self-administration of Subcutaneous Elranatamab in the Patients' Homes. treatment 2 not_yet_recruiting NCT02086942
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. treatment 2 unknown_status NCT00507442
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients treatment 1 / 2 completed NCT00446342
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies treatment 1 completed NCT04309942
Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment No drug interventions treatment Not Available completed NCT00352742
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma treatment 1 / 2 terminated NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT02343042
Selinexor and Backbone Treatments of Multiple Myeloma Patients treatment 1 / 2 active_not_recruiting NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT04975399
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma No drug interventions treatment 1 active_not_recruiting NCT02452099
Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. No drug interventions treatment Not Available completed NCT05560399
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma treatment 0 enrolling_by_invitation NCT04645199
National Longitudinal Cohort of Hematological Diseases No drug interventions Not Available Not Available recruiting NCT06523699
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant treatment 1 not_yet_recruiting NCT01610999
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation treatment 1 terminated NCT03016806
Umbilical Cord Blood Transplantation From Unrelated Donors treatment 1 recruiting NCT03638206
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies No drug interventions treatment 1 / 2 unknown_status NCT02416206
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma No drug interventions treatment 2 completed NCT00103506
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma treatment 3 completed NCT02812706
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients treatment 1 / 2 completed NCT04483206
Personalized Autologous Transplant for Multiple Myeloma treatment 1 recruiting NCT00366106
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma treatment 2 terminated NCT06515249
Integrative Therapies in Multiple Myeloma No drug interventions supportive_care Not Available recruiting NCT01053949
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma treatment 2 completed NCT00998049
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant treatment 2 completed NCT02157636
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma treatment 1 completed NCT00622336
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma treatment 3 completed NCT01801436
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma treatment 3 completed NCT01672736
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma treatment 1 / 2 terminated NCT04855136
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT05888636
Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT00276536
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma treatment 1 completed NCT03188536
Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) No drug interventions Not Available Not Available completed NCT01328236
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia treatment 2 unknown_status NCT05697913
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation No drug interventions treatment Not Available active_not_recruiting NCT00124813
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma treatment 2 unknown_status NCT04674813
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT02011113
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma treatment 2 completed NCT00111813
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) treatment 1 completed NCT01653418
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation treatment 2 terminated NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) treatment 1 recruiting NCT00044018
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT00038818
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation No drug interventions treatment Not Available terminated NCT04432818
Digital Life Coaching for Myeloma Patients Undergoing Transplantation No drug interventions supportive_care Not Available completed NCT00729118
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 completed NCT00530218
Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant supportive_care 2 completed NCT01199718
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 unknown_status NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors treatment 2 completed NCT02078518
Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors No drug interventions Not Available Not Available unknown_status NCT00718419
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma treatment 2 completed NCT01772719
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid treatment Not Available terminated NCT00303719
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy treatment 2 terminated NCT00581919
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma treatment 2 completed NCT00412919
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT02951819
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma treatment 2 completed NCT01348919
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT01345019
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma supportive_care 3 completed NCT02240719
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer treatment 1 completed NCT00602641
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma treatment 3 active_not_recruiting NCT00116441
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma No drug interventions treatment 1 / 2 completed NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT05618041
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies No drug interventions treatment Not Available recruiting NCT04191941
Treatment of Hematological Malignancy With Novel CAR-T Cells. No drug interventions treatment 0 unknown_status NCT02722941
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) treatment 2 completed NCT06187441
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) treatment 3 recruiting NCT00652041
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma treatment 4 completed NCT03720041
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma treatment 3 recruiting NCT01675141
Lenalidomide Maintenance Therapy for Multiple Myeloma treatment 2 terminated NCT02288741
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy treatment 3 completed NCT01658241
Panobinostat Biological Correlates Study basic_science 2 completed NCT02182141
An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT02204241
Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients treatment 1 / 2 completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT02045017
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency treatment 2 completed NCT00148317
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma treatment 2 completed NCT03126617
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma Not Available Not Available no_longer_available NCT03225417
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. treatment 1 / 2 active_not_recruiting NCT01042717
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection treatment Not Available unknown_status NCT02951117
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment treatment 1 withdrawn NCT00579917
Behavioral Intervention For BMT/SCT Survivors No drug interventions Not Available Not Available completed NCT03758417
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma treatment 2 recruiting NCT06463717
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not No drug interventions Not Available Not Available recruiting NCT01374217
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma treatment 2 terminated NCT06154317
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM) No drug interventions Not Available Not Available recruiting NCT05968417
Myeloma Novel Drug Discovery Ver 1.2 No drug interventions Not Available Not Available recruiting NCT02791217
Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool No drug interventions Not Available Not Available unknown_status NCT06517017
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma treatment 2 not_yet_recruiting NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT01309334
Imaging Young Myeloma (IMAgerie JEune Myélome) No drug interventions diagnostic 3 completed NCT03221634
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) treatment 2 withdrawn NCT01370434
Two Cycles of PAD Combination by AHCT in MM treatment 2 completed NCT03823534
Post-Op Pain Control for Prophylactic Intramedullary Nailing. treatment 3 recruiting NCT01859234
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma diagnostic Not Available unknown_status NCT06116734
Lapelga vs Gastrofil treatment 3 not_yet_recruiting NCT01965834
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma treatment 2 terminated NCT00858234
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) treatment 1 completed NCT01146834
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma treatment 3 completed NCT03000634
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy treatment 2 withdrawn NCT02481934
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma treatment 1 completed NCT05775224
ASH Research Collaborative Data Hub No drug interventions Not Available Not Available enrolling_by_invitation NCT05299424
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 not_yet_recruiting NCT01517724
Bortezomib Consolidation Trial treatment 2 completed NCT00857324
Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients treatment 1 / 2 terminated NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) treatment 2 unknown_status NCT04364724
CTFEA Myeloma Study No drug interventions Not Available Not Available unknown_status NCT01850524
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma treatment 3 completed NCT04302324
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab treatment 2 recruiting NCT06504524
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US Not Available Not Available completed NCT06069024
Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide No drug interventions Not Available Not Available completed NCT03804424
64Cu-LLP2A for Imaging Multiple Myeloma No drug interventions diagnostic 0 recruiting NCT00965224
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma No drug interventions treatment 2 unknown_status NCT03215524
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide treatment 2 completed NCT04650724
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor No drug interventions treatment 0 completed NCT01421524
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma treatment 1 completed NCT01602224
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) treatment 2 completed NCT03106324
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant Not Available Not Available active_not_recruiting NCT05393024
Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy Not Available Not Available completed NCT01110824
Prevention of Left Ventricular Dysfunction During Chemotherapy prevention 3 completed NCT01830816
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment treatment 1 completed NCT02315716
Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma No drug interventions treatment 2 active_not_recruiting NCT05002816
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma treatment 1 / 2 recruiting NCT00186316
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells No drug interventions treatment 1 / 2 completed NCT01609816
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma treatment 1 terminated NCT04025216
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers treatment 1 terminated NCT03150316
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma treatment 1 unknown_status NCT00325416
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. treatment 1 / 2 completed NCT05556616
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma treatment 1 completed NCT00507416
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone treatment 3 completed NCT01508416
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma No drug interventions Not Available Not Available completed NCT05448196
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma No drug interventions health_services_research Not Available completed NCT05530096
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD No drug interventions Not Available Not Available not_yet_recruiting NCT01325896
Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON) treatment 2 unknown_status NCT00577096
Effects of Exercise in Combination With Epoetin Alfa supportive_care Not Available completed NCT03723096
Expanded Access for CC-4047 Not Available Not Available no_longer_available NCT05908396
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma No drug interventions treatment 1 terminated NCT03385096
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT treatment 2 / 3 unknown_status NCT01093196
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients treatment 3 active_not_recruiting NCT00968396
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts treatment 2 withdrawn NCT02075996
Non-interventional Study With Pomalidomide (Imnovid®) No drug interventions Not Available Not Available completed NCT00626496
Family Study of Lymphoproliferative Disorders No drug interventions Not Available Not Available recruiting NCT02516696
BiRd vs. Rd as Initial Therapy in Multiple Myeloma treatment 3 terminated NCT05172596
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT01241396
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure No drug interventions Not Available Not Available completed NCT04174196
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma treatment 2 active_not_recruiting NCT00048958
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma No drug interventions Not Available Not Available active_not_recruiting NCT05064358
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT04212858
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma No drug interventions diagnostic Not Available unknown_status NCT01677858
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma treatment 1 / 2 completed NCT04604158
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients No drug interventions supportive_care Not Available completed NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies treatment 1 / 2 completed NCT06216158
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma treatment 3 recruiting NCT00916058
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma treatment 1 / 2 completed NCT05679258
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects treatment 1 completed NCT05646758
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects No drug interventions treatment 1 recruiting NCT01858558
Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma No drug interventions treatment 2 completed NCT01177735
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma treatment 2 completed NCT01559935
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma treatment 2 active_not_recruiting NCT03322735
Study of BCMA CAR-T in Multiple Myeloma treatment 1 / 2 unknown_status NCT02103335
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma treatment 1 completed NCT00443235
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old treatment 3 completed NCT04634435
Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients treatment 1 recruiting NCT03602235
High Dose Ascorbic Acid for Plasma Cell Disorders treatment 1 recruiting NCT03234335
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment No drug interventions Not Available Not Available completed NCT00388635
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. treatment 1 / 2 completed NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT05346835
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma Not Available Not Available available NCT03524235
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL treatment 1 active_not_recruiting NCT04521335
Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma treatment 1 terminated NCT04388735
Multiple Myeloma (MM) Quality of Life (QOL) Study No drug interventions Not Available Not Available unknown_status NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT02573935
Clarithromycin in Multiple Myeloma Induction Therapy treatment 2 terminated NCT06039735
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT00898235
Collection of Samples and Clinical Data From Patients With Amyloid Diseases No drug interventions Not Available Not Available recruiting NCT01999335
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma treatment 1 terminated NCT05972135
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma treatment 2 recruiting NCT05093335
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET No drug interventions diagnostic 0 recruiting NCT05036863
Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists No drug interventions Not Available Not Available completed NCT02072863
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma treatment 1 / 2 completed NCT02474563
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Not Available Not Available completed NCT01782963
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) treatment 2 completed NCT00120263
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma No drug interventions treatment Not Available completed NCT04236063
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors No drug interventions Not Available Not Available completed NCT05820763
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant treatment 2 withdrawn NCT02579863
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) treatment 3 terminated NCT01408563
Reduced Intensity Double Umbilical Cord Blood Transplantation treatment 2 completed NCT00339963
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma No drug interventions Not Available Not Available completed NCT02217163
Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT01314963
Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy No drug interventions diagnostic Not Available completed NCT05850286
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities No drug interventions treatment 2 recruiting NCT00997386
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States treatment 2 completed NCT00307086
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants treatment 2 completed NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No drug interventions Not Available Not Available recruiting NCT03983486
Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma No drug interventions Not Available Not Available withdrawn NCT00928486
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma treatment 3 completed NCT01731886
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma treatment 4 completed NCT01421186
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT02831686
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma treatment 1 completed NCT05208086
Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT00648739
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM treatment 1 / 2 terminated NCT03910439
Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma treatment 2 terminated NCT04483739
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) treatment 3 active_not_recruiting NCT01449539
Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization No drug interventions treatment Not Available terminated NCT02514239
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients treatment 1 completed NCT00081939
UARK 2003-33, Total Therapy III treatment 2 completed NCT00847639
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma treatment 2 completed NCT00919139
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. No drug interventions Not Available Not Available completed NCT00067639
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma prevention 2 completed NCT05183139
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma treatment 4 withdrawn NCT00854139
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD) treatment 1 completed NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT02406222
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) treatment 2 unknown_status NCT02289222
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 terminated NCT03110822
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients treatment 1 recruiting NCT00761722
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma treatment 1 completed NCT06083922
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) treatment 2 recruiting NCT03015922
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma treatment 1 unknown_status NCT02661022
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma treatment 1 / 2 terminated NCT00378222
Autologous Transplantation for Multiple Myeloma No drug interventions treatment 3 completed NCT05150522
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma No drug interventions treatment 1 / 2 unknown_status NCT04864522
Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 / 2 withdrawn NCT04234022
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma Not Available Not Available recruiting NCT05308225
Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 active_not_recruiting NCT02462525
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma treatment 1 terminated NCT03702725
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT02244125
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial treatment 2 completed NCT02402725
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma treatment 2 withdrawn NCT02206425
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients treatment 1 / 2 completed NCT01408225
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource No drug interventions Not Available Not Available recruiting NCT05578625
ctDNA Methylation Sequencing for Myeloma No drug interventions Not Available Not Available recruiting NCT01314625
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients No drug interventions Not Available Not Available unknown_status NCT04273425
Bone Pain in Multiple Myeloma- a Translational Study No drug interventions Not Available Not Available unknown_status NCT00176930
Stem Cell Transplant for Hematological Malignancy treatment Not Available terminated NCT02609230
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma treatment 1 completed NCT02128230
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission treatment 2 terminated NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT02773030
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT00048230
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma treatment 3 completed NCT01242930
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma treatment 2 completed NCT05271630
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT02286830
Prolonged Protection From Bone Disease in Multiple Myeloma treatment 4 completed NCT01062230
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma treatment 2 terminated NCT01913730
Maintenance Therapy With Subcutaneous Bortezomib treatment 2 completed NCT00999830
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma treatment 2 completed NCT05690230
Improving Patient Experience: BMBA No drug interventions supportive_care Not Available active_not_recruiting NCT00520130
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System treatment 1 / 2 completed NCT01002248
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients treatment 3 terminated NCT03361748
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma treatment 2 completed NCT00909948
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial treatment 3 active_not_recruiting NCT02291848
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma No drug interventions treatment 1 recruiting NCT00111748
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients treatment 3 completed NCT05028348
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma treatment 3 recruiting NCT05643248
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects No drug interventions treatment 0 completed NCT01094548
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy treatment 2 completed NCT06581848
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). Not Available Not Available not_yet_recruiting NCT00002548
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma treatment 3 completed NCT00996957
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT04071457
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration treatment 3 recruiting NCT01572857
Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma No drug interventions Not Available Not Available completed NCT03091257
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma treatment 1 recruiting NCT02100657
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma other 1 completed NCT01217957
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma treatment 1 / 2 completed NCT02315157
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma treatment 1 withdrawn NCT00315757
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT00081757
An Open Protocol for the Compassionate Use of Thalidomide treatment 1 / 2 completed NCT04191057
Determining Normal Range for Free Light Chains in Serum Among Twins No drug interventions screening Not Available completed NCT00185757
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation No drug interventions treatment 1 unknown_status NCT00193557
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma treatment 2 completed NCT01359657
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT01985126
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD treatment 2 completed NCT04091126
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma treatment 1 recruiting NCT03200626
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma No drug interventions Not Available Not Available completed NCT05835726
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. Not Available Not Available recruiting NCT04035226
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment No drug interventions Not Available Not Available completed NCT04504526
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases No drug interventions diagnostic 0 recruiting NCT00063726
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 treatment 3 completed NCT00626626
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation treatment 1 / 2 terminated NCT04756726
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma treatment 1 / 2 recruiting NCT03147326
Diagnostic Imaging of Myeloma Bone Lesions No drug interventions diagnostic Not Available completed NCT00594126
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma treatment 1 completed NCT03019666
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL treatment 1 completed NCT00231166
Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma treatment 1 completed NCT05090566
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma treatment 2 recruiting NCT05706766
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation No drug interventions supportive_care Not Available recruiting NCT01568866
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients treatment 3 completed NCT00270166
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy treatment 3 completed NCT00722566
A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma treatment 3 completed NCT01208766
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma treatment 3 active_not_recruiting NCT00427765
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma treatment 2 completed NCT00440765
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Not Available Not Available completed NCT01969565
Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma treatment 2 terminated NCT00319865
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma treatment 2 unknown_status NCT03433365
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) No drug interventions Not Available Not Available completed NCT04166565
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease treatment 2 active_not_recruiting NCT02566265
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients treatment 2 completed NCT02362165
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma treatment 3 unknown_status NCT00078065
Xcellerated T CellsTM in Patients With Multiple Myeloma No drug interventions treatment 2 completed NCT01303965
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) treatment 1 / 2 terminated NCT01647165
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance treatment 2 withdrawn NCT00834665
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma No drug interventions treatment 1 completed NCT02843074
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients treatment 2 completed NCT01268774
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. No drug interventions Not Available Not Available completed NCT05896774
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China treatment 1 active_not_recruiting NCT01019174
Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT03288974
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea Not Available Not Available recruiting NCT06182774
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma treatment 3 recruiting NCT01234974
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus treatment 2 withdrawn NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT01435720
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) treatment 1 / 2 unknown_status NCT00153920
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma treatment 2 completed NCT00963820
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma treatment 1 completed NCT02322320
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) treatment 3 completed NCT02916420
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma treatment 3 unknown_status NCT04506320
Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma No drug interventions Not Available Not Available completed NCT05556720
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial treatment 3 recruiting NCT01114282
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM treatment 1 completed NCT05986682
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma Not Available Not Available completed NCT00667082
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma other 1 completed NCT01622582
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma No drug interventions Not Available Not Available completed NCT06474182
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma other Not Available not_yet_recruiting NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT01479582
Providing Access to Cord Blood Units for Transplants No drug interventions treatment 2 withdrawn NCT01713582
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) treatment 1 completed NCT01091831
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects treatment 3 active_not_recruiting NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT04570631
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT01315873
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma treatment 2 terminated NCT02952573
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement treatment 2 terminated NCT03670173
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma treatment 1 / 2 unknown_status NCT00416273
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma treatment 3 completed NCT00123773
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence No drug interventions diagnostic 2 completed NCT00001873
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers No drug interventions treatment 2 completed NCT06236373
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia No drug interventions Not Available Not Available recruiting NCT01177527
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders No drug interventions Not Available Not Available active_not_recruiting NCT03023527
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma treatment 1 terminated NCT04318327
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma treatment 1 active_not_recruiting NCT05130827
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) treatment 2 active_not_recruiting NCT01832727
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT03091127
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe No drug interventions Not Available Not Available completed NCT04912427
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease treatment 1 terminated NCT04181827
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma treatment 3 active_not_recruiting NCT01018927
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects No drug interventions Not Available Not Available terminated NCT06520176
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients treatment 3 recruiting NCT00809276
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY treatment 1 / 2 completed NCT02967276
Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma treatment 2 unknown_status NCT06251076
Plan Development for Giving Teclistamab in the Outpatient Setting treatment 4 not_yet_recruiting NCT01344876
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies No drug interventions treatment 1 completed NCT01701076
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT01886976
Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 No drug interventions treatment 1 / 2 unknown_status NCT00320476
VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates treatment 2 completed NCT01979276
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma treatment 1 / 2 terminated NCT00083876
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma treatment 3 completed NCT06485076
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma No drug interventions supportive_care Not Available recruiting NCT00256776
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation treatment 3 terminated NCT03941860
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial treatment 3 active_not_recruiting NCT02589860
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant No drug interventions Not Available Not Available withdrawn NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT01045460
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma treatment 2 completed NCT02043860
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma treatment 1 terminated NCT00833560
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy treatment 2 completed NCT04121260
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma treatment 1 completed NCT05969860
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer No drug interventions health_services_research 2 recruiting NCT04287660
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients treatment 3 recruiting NCT00083460
Study of Combination PS-341 and Thalidomide in Multiple Myeloma treatment 1 completed NCT03768960
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent treatment 4 completed NCT00091260
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis treatment 2 completed NCT02739594
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma treatment 3 terminated NCT01530594
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma treatment 3 completed NCT00460694
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies No drug interventions treatment 1 / 2 completed NCT00382694
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients treatment 2 unknown_status NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases No drug interventions treatment 0 recruiting NCT00573391
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 treatment 3 terminated NCT04303091
The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients No drug interventions other Not Available completed NCT02863991
Oral ONC201 in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 terminated NCT00617591
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) treatment 2 completed NCT05565391
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma Not Available Not Available completed NCT05055791
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 / 2 not_yet_recruiting NCT02169791
Nonmyeloablative Haploidentical Transplant Followed by MLN9708 prevention 2 completed NCT00560391
Dasatinib in Combination With Revlimid (and Dexamethasone) treatment 1 completed NCT03110562
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma treatment 3 completed NCT01811862
Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients No drug interventions treatment Not Available completed NCT02597062
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma treatment 2 completed NCT02561962
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 completed NCT00240162
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma treatment 2 terminated NCT05414162
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy No drug interventions Not Available Not Available recruiting NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT02212262
Role of Osteocytes in Myeloma Bone Disease No drug interventions Not Available Not Available completed NCT03809780
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone treatment 2 active_not_recruiting NCT00570180
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma treatment 2 completed NCT02391480
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer treatment 1 completed NCT04398680
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function treatment 1 recruiting NCT04935580
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients No drug interventions treatment 1 / 2 unknown_status NCT02358980
Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy No drug interventions Not Available Not Available unknown_status NCT04840680
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) No drug interventions Not Available Not Available completed NCT06060080
Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma treatment Not Available recruiting NCT01160380
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma supportive_care 3 completed NCT03246529
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) treatment 3 active_not_recruiting NCT04436029
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy No drug interventions treatment 2 completed NCT02658929
Study of bb2121 in Multiple Myeloma treatment 1 completed NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT04835129
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma treatment 2 recruiting NCT03871829
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab treatment 2 terminated NCT05412329
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma No drug interventions treatment 1 unknown_status NCT04678089
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics Not Available Not Available unknown_status NCT04412889
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM No drug interventions treatment 0 unknown_status NCT01090089
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma treatment 3 completed NCT01712789
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma treatment 3 completed NCT00615589
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen treatment 2 terminated NCT01980589
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects treatment 1 completed NCT03828292
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments treatment 1 active_not_recruiting NCT02572492
Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support treatment 2 unknown_status NCT00005792
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma treatment 1 completed NCT01021592
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Not Available Not Available completed NCT01241292
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone treatment 1 completed NCT03173092
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) treatment 4 active_not_recruiting NCT04561492
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma diagnostic 2 recruiting NCT03409692
Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients No drug interventions Not Available Not Available completed NCT01953692
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) treatment 1 completed NCT04122092
Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma No drug interventions Not Available Not Available unknown_status NCT04746092
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 No drug interventions Not Available Not Available unknown_status NCT02451592
Fungemia in Hematologic Malignancies No drug interventions Not Available Not Available completed NCT03111992
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma treatment 1 completed NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT treatment 2 completed NCT04322292
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma No drug interventions treatment 1 unknown_status NCT04891744
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM treatment 1 / 2 not_yet_recruiting NCT03717844
Registry for Adults With Plasma Cell Disorders (PCD's) No drug interventions Not Available Not Available recruiting NCT00701844
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors No drug interventions treatment Not Available completed NCT04271644
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT00193544
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma treatment 2 completed NCT03490344
Short Course Daratumumab in Patients With Multiple Myeloma treatment 2 completed NCT01541644
1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma No drug interventions supportive_care Not Available completed NCT03539744
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. treatment 3 active_not_recruiting NCT02406144
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma treatment 3 completed NCT05020444
TriPRIL CAR T Cells in Multiple Myeloma treatment 1 recruiting NCT01054144
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma treatment 2 completed NCT00681044
HD Melphalan and SCT in Patients With IGDD or LCDD treatment 2 terminated NCT01423344
Clinical Evaluation of the Serum Free Light Chain Analysis No drug interventions Not Available Not Available unknown_status NCT01009840
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients treatment 2 completed NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies treatment 1 terminated NCT02372240
A Study of VLX1570 and Dexamethasone in Myeloma Patients treatment 1 / 2 terminated NCT00036140
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma No drug interventions treatment 1 completed NCT01947140
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies treatment 1 / 2 completed NCT02140840
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib treatment 2 withdrawn NCT00417040
Collection of Patient-Reported Symptoms and Performance Status Via the Internet No drug interventions other Not Available completed NCT05527340
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. treatment 2 not_yet_recruiting NCT00431340
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma treatment 2 terminated NCT02616640
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT04989140
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide treatment 4 unknown_status NCT04405167
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma treatment 1 recruiting NCT00395967
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone treatment 2 terminated NCT00087867
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma treatment 2 completed NCT00679367
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis treatment 2 completed NCT00299767
Phase I Study of Sequential Cord Blood Transplants No drug interventions treatment 1 completed NCT03486067
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT00133367
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus treatment 2 completed NCT02546167
CART-BCMA Cells for Multiple Myeloma No drug interventions treatment 1 completed NCT04217967
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients treatment 4 completed NCT01242267
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT treatment 1 / 2 completed NCT05996367
Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma No drug interventions treatment Not Available recruiting NCT06160167
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs No drug interventions Not Available Not Available completed NCT00961467
RMPT for Relapsed/Refractory Multiple Myeloma treatment 2 completed NCT02368301
Expanded Access Treatment Protocol CA204-143 Not Available Not Available no_longer_available NCT01026701
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Not Available Not Available completed NCT02168101
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma treatment 2 completed NCT01376401
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma treatment 2 completed NCT05325801
A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 not_yet_recruiting NCT05181501
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) treatment 1 not_yet_recruiting NCT04099901
Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial supportive_care 2 active_not_recruiting NCT00104104
A Multiple Myeloma Trial in Patients With Bone Metastases treatment 4 completed NCT00691704
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy treatment 2 completed NCT03287804
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma No drug interventions treatment 1 / 2 terminated NCT00973804
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders treatment 1 terminated NCT04617704
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma No drug interventions treatment 0 unknown_status NCT03850704
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma Not Available Not Available no_longer_available NCT01296204
Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131 treatment 1 completed NCT00547404
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma No drug interventions treatment 1 withdrawn NCT02628704
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma treatment 2 withdrawn NCT00113204
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma treatment 1 completed NCT03001804
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients No drug interventions Not Available Not Available completed NCT01339572
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation supportive_care 2 completed NCT02924272
Ixazomib Rollover Study treatment 2 completed NCT00580372
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma treatment 2 completed NCT03234972
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma treatment 3 completed NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT02976272
Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple No drug interventions Not Available Not Available unknown_status NCT00903968
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT02188368
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients treatment 2 terminated NCT04003168
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 unknown_status NCT02331368
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma treatment 2 completed NCT00445068
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma treatment 2 terminated NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep treatment 2 active_not_recruiting NCT01343368
Preservation of Ovarian Function After Hematopoietic Cell Transplant supportive_care 2 terminated NCT00950768
Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients No drug interventions treatment 3 completed NCT06296368
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics No drug interventions health_services_research Not Available not_yet_recruiting NCT03093168
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma treatment 1 unknown_status NCT00577668
A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) prevention 2 withdrawn NCT01349569
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission treatment 2 completed NCT00572169
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy treatment 3 active_not_recruiting NCT02116569
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT00726869
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. treatment 1 terminated NCT05006469
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma treatment 3 unknown_status NCT00431769
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma treatment 2 completed NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies treatment 1 recruiting NCT01416246
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant No drug interventions treatment Not Available completed NCT06340646
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) No drug interventions health_services_research Not Available recruiting NCT04830046
Covid-19 Vaccine Responsiveness in MM and Waldenstrom No drug interventions Not Available Not Available unknown_status NCT00592046
A Phase I Trial of ZIO-101 in Hematologic Cancers treatment 1 completed NCT06452446
Telehealth-based Symptom Management for Veterans Treated With Selinexor Not Available Not Available not_yet_recruiting NCT06223646
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT05066646
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) treatment 1 / 2 unknown_status NCT02794246
CART-19 Post-ASCT for Multiple Myeloma treatment 2 terminated NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignancies treatment 1 completed NCT01430546
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line No drug interventions Not Available Not Available completed NCT00048412
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H treatment 1 / 2 completed NCT03217812
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) treatment 3 completed NCT02439112
Exercise in Patients With Multiple Myeloma No drug interventions supportive_care Not Available completed NCT06099912
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM No drug interventions Not Available Not Available recruiting NCT01838512
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) No drug interventions Not Available Not Available recruiting NCT03993912
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy treatment 3 active_not_recruiting NCT01374412
Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging No drug interventions Not Available Not Available unknown_status NCT02619812
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT supportive_care 2 terminated NCT00884312
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols treatment 2 completed NCT05014412
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment treatment 2 active_not_recruiting NCT05243212
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT01829412
Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma No drug interventions diagnostic Not Available completed NCT02467010
Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance treatment 2 completed NCT01593410
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma treatment 2 completed NCT00861510
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies treatment 1 completed NCT00871910
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) treatment 1 completed NCT02955810
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) treatment 1 unknown_status NCT05645510
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study No drug interventions Not Available Not Available recruiting NCT02626481
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma treatment 2 completed NCT05366881
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease No drug interventions Not Available Not Available recruiting NCT03276481
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation No drug interventions Not Available Not Available completed NCT06145581
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma No drug interventions supportive_care Not Available not_yet_recruiting NCT02660281
URMC Related Haplo-identical Donor BMT treatment 1 completed NCT03314181
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT01699581
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant No drug interventions treatment 2 terminated NCT04182581
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma No drug interventions treatment 0 unknown_status NCT01492881
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma treatment 2 withdrawn NCT03191981
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma treatment 1 / 2 withdrawn NCT04467281
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma diagnostic 2 withdrawn NCT01478581
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma treatment 2 completed NCT00083681
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse treatment 2 completed NCT01410981
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma No drug interventions Not Available Not Available completed NCT00097981
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma treatment 3 completed NCT02918695
Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients No drug interventions Not Available Not Available completed NCT03875495
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) No drug interventions treatment 1 / 2 terminated NCT00290095
Quality of Life in Patients With Multiple Myeloma No drug interventions Not Available Not Available completed NCT04108195
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma treatment 1 active_not_recruiting NCT01582295
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease treatment 1 completed NCT04045795
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) treatment 1 completed NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy treatment 1 terminated NCT03689595
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) No drug interventions Not Available Not Available recruiting NCT03196414
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT00586014
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma No drug interventions treatment 2 completed NCT04484714
Virtual Exercise for Multiple Myeloma No drug interventions supportive_care Not Available completed NCT03891914
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma diagnostic 3 unknown_status NCT00999414
UARK 2009-32 Compassionate Use Study of Carfilzomib Not Available Not Available no_longer_available NCT02328014
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies treatment 1 / 2 active_not_recruiting NCT00185614
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma treatment 2 completed NCT01484314
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma treatment 2 terminated NCT02519114
Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma No drug interventions treatment 1 / 2 unknown_status NCT04674514
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT02447055
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma treatment 0 withdrawn NCT03383055
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig No drug interventions treatment 1 completed NCT03602755
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain No drug interventions Not Available Not Available completed NCT05294055
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma treatment 2 recruiting NCT00378755
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM treatment 2 unknown_status NCT02164955
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma. Not Available Not Available completed NCT03697655
Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma prevention 2 unknown_status NCT00920855
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT03779555
Lenalidomide Adherence in Older Adults No drug interventions Not Available Not Available terminated NCT04975555
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy treatment 2 recruiting NCT03665155
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody diagnostic 1 / 2 completed NCT00218855
Thalidomide to Patients With Previously Untreated Multiple Myeloma treatment 3 completed NCT03290950
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma treatment 2 active_not_recruiting NCT03201250
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma treatment 1 / 2 terminated NCT02773550
Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma treatment 4 terminated NCT04609150
Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI) No drug interventions Not Available Not Available unknown_status NCT04557150
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) treatment 1 recruiting NCT05974150
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring No drug interventions Not Available Not Available recruiting NCT04847050
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy prevention 2 completed NCT02955550
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) treatment 1 completed NCT02435550
iCare for Cancer Patients No drug interventions diagnostic Not Available terminated NCT00012350
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma treatment 2 completed NCT06338150
Precision Medicine Study No drug interventions Not Available Not Available recruiting NCT06048250
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma treatment 1 recruiting NCT01660750
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma treatment 1 completed NCT02457650
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies treatment 1 unknown_status NCT05841550
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT04184050
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) No drug interventions treatment 1 active_not_recruiting NCT00036023
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies treatment 2 completed NCT04484623
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma treatment 3 recruiting NCT00001623
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia No drug interventions treatment Not Available completed NCT00784823
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma treatment 1 / 2 completed NCT02426723
Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients treatment 1 completed NCT03018223
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT prevention 1 completed NCT04872023
Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression No drug interventions basic_science Not Available completed NCT01087008
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse prevention 4 completed NCT00075608
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis treatment 2 terminated NCT05431608
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma No drug interventions treatment 1 recruiting NCT05695508
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 treatment 2 recruiting NCT04727008
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma treatment 1 recruiting NCT06348108
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma treatment 1 not_yet_recruiting NCT06514508
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients treatment 3 not_yet_recruiting NCT01148108
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma treatment 2 completed NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD treatment Not Available terminated NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia treatment 2 recruiting NCT05995808
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests No drug interventions diagnostic Not Available not_yet_recruiting NCT02537808
Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma No drug interventions Not Available Not Available completed NCT01023308
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma treatment 3 completed NCT00729638
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT00572338
Therapeutic Research in Multiple Myeloma No drug interventions Not Available Not Available completed NCT02528838
An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide. No drug interventions Not Available Not Available completed NCT05620238
Home Treatment With Carfilzomib in Patients With Multiple Myeloma Not Available Not Available recruiting NCT01352338
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) treatment 1 / 2 completed NCT00064038
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma treatment 3 completed NCT02856438
Early Patient Access Treatment Use Protocol CA204-220 Not Available Not Available no_longer_available NCT00186238
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma No drug interventions treatment 2 completed NCT00733538
Stage I Multiple Myeloma Treatment treatment 4 completed NCT04004338
Carfilzomib in Combination for the Treatment of RR MM Not Available Not Available unknown_status NCT02568943
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma Not Available Not Available no_longer_available NCT04985643
A Study of Real Life Treatment for Multiple Myeloma (MM) No drug interventions Not Available Not Available recruiting NCT00215943
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) treatment 3 terminated NCT02189343
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma other 1 completed NCT00967343
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor No drug interventions prevention 2 / 3 terminated NCT05478343
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma No drug interventions treatment 0 unknown_status NCT00401843
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT02922543
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use No drug interventions Not Available Not Available completed NCT04552743
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma treatment 2 completed NCT01720043
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients treatment 2 terminated NCT01690143
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation treatment 1 / 2 completed NCT04991103
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) treatment 2 recruiting NCT00151203
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma treatment 2 completed NCT01002703
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 unknown_status NCT03710603
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma treatment 3 active_not_recruiting NCT00590603
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 terminated NCT06237803
European Myeloma Network (EMN) Sample Project No drug interventions Not Available Not Available recruiting NCT05218603
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT Not Available Not Available recruiting NCT03275103
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) treatment 1 recruiting NCT05698303
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma treatment 1 not_yet_recruiting NCT01274403
A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma Not Available 2 completed NCT04564703
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients treatment 2 active_not_recruiting NCT04898790
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant No drug interventions treatment Not Available recruiting NCT00304590
Study of XL999 in Patients With Multiple Myeloma treatment 2 terminated NCT01504490
Phase I Study of CS-7017 and Bexarotene treatment 1 terminated NCT01249690
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma treatment 4 unknown_status NCT02268890
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma treatment 4 completed NCT04393090
eHealth for the Elderly No drug interventions Not Available Not Available completed NCT02654990
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma treatment 2 completed NCT01695590
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma treatment 1 / 2 unknown_status NCT00431990
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma treatment 1 / 2 unknown_status NCT00205764
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy treatment 3 completed NCT06457464
Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients No drug interventions Not Available Not Available not_yet_recruiting NCT01716364
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 unknown_status NCT01393964
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function treatment 1 completed NCT00415064
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma treatment 1 completed NCT02898064
Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace No drug interventions treatment Not Available completed NCT00057564
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma treatment 3 completed NCT02440464
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) treatment 2 completed NCT01297764
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT03711864
Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma No drug interventions treatment 1 unknown_status NCT04014764
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy No drug interventions Not Available Not Available completed NCT02578121
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination treatment 2 withdrawn NCT00075621
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis treatment 2 completed NCT02719821
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation No drug interventions supportive_care Not Available completed NCT04075721
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone No drug interventions treatment 1 terminated NCT02197221
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma treatment 3 completed NCT06296121
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma treatment 3 recruiting NCT01908621
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. treatment 3 completed NCT01090921
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma treatment 2 completed NCT06552221
Finistere Myeloma Observatory (OMYFIN) No drug interventions Not Available Not Available completed NCT00582621
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders No drug interventions Not Available Not Available recruiting NCT05497102
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT treatment 2 recruiting NCT00775502
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma No drug interventions treatment 1 terminated NCT02036502
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) treatment 1 terminated NCT06154902
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel Not Available Not Available active_not_recruiting NCT01754402
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT01060202
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Not Available Not Available completed NCT00871702
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease No drug interventions treatment 1 completed NCT02681302
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence treatment 1 / 2 terminated NCT00765102
Trial of Romidepsin and Bortezomib for Multiple Myeloma treatment 2 terminated NCT02158702
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib treatment 2 unknown_status NCT01792102
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma treatment 1 / 2 unknown_status NCT00892502
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? No drug interventions treatment Not Available completed NCT01160484
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma treatment 2 completed NCT02434484
Symbenda Post-Marketing Surveillance (PMS) No drug interventions Not Available Not Available completed NCT00531284
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma treatment 1 / 2 completed NCT03379584
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma No drug interventions treatment 1 terminated NCT04114084
Sleep Apnea in Patients With MGUS and MM No drug interventions Not Available Not Available recruiting NCT00143884
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood No drug interventions educational_counseling_training 2 terminated NCT03490084
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT00006184
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma treatment 2 completed NCT02507479
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies treatment 2 unknown_status NCT03815279
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) treatment 2 enrolling_by_invitation NCT05860179
Examination of Trends in Multiple Myeloma Trial Patient Experiences No drug interventions Not Available Not Available not_yet_recruiting NCT02221479
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma treatment 2 completed NCT02703779
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) treatment 2 completed NCT04135079
Immune Profiling in Multiple Myeloma No drug interventions Not Available Not Available active_not_recruiting NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT04960579
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma treatment 1 recruiting NCT00440479
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Not Available Not Available completed NCT02387879
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR No drug interventions Not Available Not Available unknown_status NCT05882279
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan No drug interventions Not Available Not Available completed NCT03004287
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy treatment 2 active_not_recruiting NCT02064387
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 treatment 1 completed NCT01346787
Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients treatment 2 completed NCT05306587
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project. Not Available Not Available completed NCT02468687
NMP in Relapsed / Refractory Myeloma treatment 1 completed NCT00322387
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients treatment 2 completed NCT01402687
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) No drug interventions Not Available Not Available completed NCT05355987
Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma No drug interventions supportive_care Not Available recruiting NCT05064787
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy No drug interventions supportive_care Not Available completed NCT06028087
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment No drug interventions Not Available Not Available not_yet_recruiting NCT01910987
Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib treatment 3 completed NCT05405387
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant treatment 2 recruiting NCT05567887
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies treatment 1 active_not_recruiting NCT00050687
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies treatment 1 / 2 terminated NCT00538733
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma treatment 2 completed NCT06559033
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS Not Available Not Available not_yet_recruiting NCT00891033
Panobinostat/Velcade in Multiple Myeloma treatment 1 terminated NCT01660633
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation treatment 2 completed NCT02946333
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain No drug interventions Not Available Not Available completed NCT01132833
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy No drug interventions Not Available Not Available completed NCT06189833
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS treatment 2 recruiting NCT05344833
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma treatment 2 recruiting NCT02718833
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma treatment 2 active_not_recruiting NCT03940833
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM No drug interventions treatment 1 / 2 unknown_status NCT00956033
Skin Biopsies in Chemotherapy-Induced Neuropathy No drug interventions Not Available Not Available completed NCT00039754
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma No drug interventions treatment 1 / 2 terminated NCT01237054
Imaging in MGUS, SMM and MM No drug interventions diagnostic 2 completed NCT00934154
Melphalan+Prednisolon With or Without Thalidomide in Previously U